共 50 条
Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency
被引:0
|作者:
Cheema, Baljash
[1
,2
]
Chokshi, Anuj
[3
]
Orimoloye, Olusola
[3
]
Ardehali, Hossein
[2
]
机构:
[1] Northwestern Med, Bluhm Cardiovasc Inst, Ctr Arti ficial Intelligence, Chicago, IL USA
[2] Northwestern Univ, Feinberg Sch Med, SQBRC 8-521,303 Super St, Chicago, IL 60611 USA
[3] Northwestern Univ, McGaw Med Ctr, Feinberg Sch Med, Chicago, IL USA
关键词:
cardiovascular outcomes;
clinical trials;
heart failure;
intravenous iron;
iron deficiency;
iron repletion;
QUALITY-OF-LIFE;
FERRIC CARBOXYMALTOSE;
EXERCISE CAPACITY;
ENDOTHELIAL DYSFUNCTION;
DARBEPOETIN-ALPHA;
MEDICAL PROGRESS;
ESC GUIDELINES;
ANEMIA;
DIAGNOSIS;
HOMEOSTASIS;
D O I:
10.1016/j.jacc.2024.03.431
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Iron deficiency and heart failure frequently co-occur, sparking clinical research into the role of iron repletion in this condition over the last 20 years. Although early nonrandomized studies and subsequent moderate -sized randomized controlled trials showed an improvement in symptoms and functional metrics with the use of intravenous iron, 3 recent larger trials powered to detect a difference in hard cardiovascular outcomes failed to meet their primary endpoints. Additionally, there are potential concerns related to side effects from intravenous iron, both in the short and long term. This review discusses the basics of iron biology and regulation, the diagnostic criteria for iron deficiency and the clinical evidence for intravenous iron in heart failure, safety concerns, and alternative therapies. We also make practical suggestions for the management of patients with iron deficiency and heart failure and outline key areas in need of future research. (J Am Coll Cardiol 2024;83:2674-2689) (c) 2024 by the American College of Cardiology Foundation.
引用
收藏
页码:2674 / 2689
页数:16
相关论文